(Illumina), and data were analyzed by Brain Tumor Methylation Classifier v11b4. 2 Our MLPA validation set comprised 3 nonneoplastic brain tissue references and 8 tumors previously examined by IDH sequencing, 1p/19q fluorescence in situ hybridization (FISH) Overall match between fast assays MLPA/PyroMark and Brain Tumor Methylation Classifier in consecutive brain tumor biopsies was high (Fig. 1A) . IDH mutations and CNVs (1p/19q; CDKN2a/b 5 ) were reliably detected by MLPA. MGMT status mainly exhibited threshold-related and CpG island-specific discrepancies (Fig. 1B) .
Whereas applicability of the fast tests is restricted by the fact that only 4 common IDH1/2 mutations are detectable (MLPA P088), and may also be compromised by low tumor cell content (PyroMark), methylomics detected IDH mutant gliomas even in samples with <30% tumor cellularity, while requiring longer turnaround times (Fig. 1C-E) .
Based on our results, we advocate a stepwise approach, providing fast-track results obtained by MLPA/PyroMark for first-line therapy decisions within a week after surgery. Whenever possible, methylome profiling should be initiated simultaneously to independently secure diagnosis, detect rare entities (eg, diffuse midline gliomas), and identify potential therapeutic targets (eg, epidermal growth factor receptor amplification). 
